Skip to main content

Main menu

  • Home
  • Current issue
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Peer reviewer login
  • Journal club
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Peer reviewer login
  • Journal club
  • Alerts
  • Subscriptions

Pulmonary arterial hypertension

M. Humbert, X. Jaïs, O. Sitbon, F. Parent, P. Hervé, G. Simonneau
Breathe 2005 2: 126-135; DOI: 10.1183/18106838.0202.126
M. Humbert
Centre des Maladies Vasculaires Pulmonaires, Hôpital Antoine-Béclére, Université Paris-Sud, Clamart, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: marc.humbert@abc.aphp.fr
X. Jaïs
Centre des Maladies Vasculaires Pulmonaires, Hôpital Antoine-Béclére, Université Paris-Sud, Clamart, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
O. Sitbon
Centre des Maladies Vasculaires Pulmonaires, Hôpital Antoine-Béclére, Université Paris-Sud, Clamart, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
F. Parent
Centre des Maladies Vasculaires Pulmonaires, Hôpital Antoine-Béclére, Université Paris-Sud, Clamart, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
P. Hervé
Centre des Maladies Vasculaires Pulmonaires, Hôpital Antoine-Béclére, Université Paris-Sud, Clamart, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
G. Simonneau
Centre des Maladies Vasculaires Pulmonaires, Hôpital Antoine-Béclére, Université Paris-Sud, Clamart, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

Key points

  • PAH is defined by RHC showing a pre-capillary PH.

  • Clinical suspicion of PH should arise in the case of symptoms such as dyspnoea without overt signs of specific heart or lung disease.

  • RHC is required to confirm the diagnosis of PAH, to assess the severity of the haemodynamic impairment and to test the vasoreactivity of the pulmonary circulation.

  • Variables that have been shown to predict prognosis in IPAH include baseline NYHA functional classification, history of right heart failure, baseline 6-minute walk distance, and baseline haemodynamics.

  • FPAH segregates as an autosomal dominant trait, but with markedly reduced penetrance. Germline BMPR2 mutations have been detected in at least 60% of the families studied to date, as well as in cases of so-called IPAH.

  • Basic PAH therapy includes oxygen, diuretics and warfarin.

  • Chronic treatment with oral CCBs should be considered for PAH patients who respond to acute vasodilator challenge.

  • Cohort analysis of IPAH patients receiving continuous intravenous epoprostenol, as compared to historical control groups, clearly demonstrated clinical benefits in NYHA functional class III and IV patients.

  • Two double-blind, randomised, placebocontrolled trials have supported the efficacy of oral bosentan in patients with PAH class III.

  • One double-blind, randomised placebocontrolled trial has supported the efficacy of oral sildenafil in patients with symptomatic PAH.

  • Lung transplantation is the ultimate alternative for severe PAH cases who cannot be managed medically.

Educational aims

  • To improve awareness of PAH.

  • To describe the novel classification of PH.

  • To provide information regarding the therapeutic approach of PAH.

Summary Pulmonary arterial hypertension (PAH) is a rare condition characterised by elevated pulmonary arterial resistance, leading to right heart failure. PAH can be sporadic (idiopathic PAH), familial or related to other conditions. Echocardiography is the investigation of choice for non-invasive screening. Measurement of haemodynamic parameters during right heart catheterisation (RHC) is mandatory to establish the diagnosis. Recent advances in the management of PAH include prostaglandins, endothelin receptor antagonists and PDE5 inhibitors. Lung transplantation is the last option for patients who deteriorate despite medical treatment. This review aims to update the reader on all these aspects of PAH.

  • ©ERS 2005

Breathe articles are open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.

PreviousNext
Back to top
Vol 2 Issue 2 Table of Contents
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Pulmonary arterial hypertension
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Pulmonary arterial hypertension
M. Humbert, X. Jaïs, O. Sitbon, F. Parent, P. Hervé, G. Simonneau
Breathe Dec 2005, 2 (2) 126-135; DOI: 10.1183/18106838.0202.126

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Pulmonary arterial hypertension
M. Humbert, X. Jaïs, O. Sitbon, F. Parent, P. Hervé, G. Simonneau
Breathe Dec 2005, 2 (2) 126-135; DOI: 10.1183/18106838.0202.126
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
  • Info & Metrics
  • PDF
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Caring for patients with advanced COPD
  • Lessons from COVID-19 in the management of acute respiratory failure
  • Management of difficult-to-treat asthma in adolescence and young adults
Show more Reviews

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About Breathe

  • Journal information
  • Editorial board
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Intructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN: 1810-6838
Online ISSN: 2073-4735

Copyright © 2023 by the European Respiratory Society